Revenue ($USD): $1,563,101,000
R&D spend: $60,800,000.00
Employees: 6,800
Fiscal year end: 12/31/22
CEO: Matthew Trerotola
Recent acquisitions include Novastepand its foot and ankle minimally invasive surgical (MIS) platform. In May, Enovis signed a definitive agreement toacquire the Seal external fixation product line from DNE.–CN